Unity Biotechnology

About Unity Biotechnology

Unity Biotechnology (NASDAQ:UBX) focuses on developing therapeutics to extend human healthspan, primarily targeting senescent cells that contribute to age-related diseases. The company is actively pursuing research and clinical trials aimed at various conditions exacerbated by aging, including ophthalmologic and neurologic diseases. One of their key objectives is to pioneer treatments that can potentially halt, reverse, or slow the processes related to aging, improving the quality of life for older populations. Unity Biotechnology's innovative approach revolves around identifying and carefully modifying the biological mechanisms of aging, setting a new frontier in medical research aimed at addressing the root causes of age-associated diseases rather than just managing their symptoms.

What is Unity Biotechnology known for?

Snapshot

2011

Year founded

Employees

South San Francisco, United States

Head office

Loading Map...

Operations

All Locations

South San Francisco, US

Products and/or services of Unity Biotechnology

Development of senolytic medicines aimed at eliminating senescent cells to treat age-related diseases.
Research on UBX1325, a small molecule inhibitor designed to treat diabetic macular edema and age-related macular degeneration.
Exploration of therapeutic agents targeting osteoarthritis with the goal of pain reduction and mobility improvement.
Investigation into pulmonary diseases, focusing on treatments that address senescence-associated diseases such as idiopathic pulmonary fibrosis.
Advancement of therapies for neurodegenerative diseases, emphasizing the potential elimination of senescent cells to halt or reverse conditions like Alzheimer's disease.
Study of kidney disease treatments involving senolytic therapies to possibly rejuvenate kidney function in chronic kidney disease patients.